News

A 27-year-old woman’s “silent” calcium deficiency due to hypoparathyroidism during pregnancy led to the surprise diagnosis of DiGeorge syndrome, a genetic disorder that had gone undetected for nearly three decades. Despite having no physical symptoms of low calcium, the woman’s persistent blood test results allowed doctors to catch the…

Entera Bio and Opko Health are teaming up to develop a once-daily oral treatment for hypoparathyroidism, known as a long-acting parathyroid hormone analog (LA-PTH). “Preclinical data of oral LA-PTH suggests that this program holds the potential to transform the hypoparathyroidism landscape,” Miranda Toledano, CEO of Entera, said…

Hypoparathyroidism was found to be the cause of unexplained leg pain for an 11-year-old girl, highlighting the importance of testing for the rare disorder in children with unexplained muscle pain, according to a case report. The case was discussed in the paper, “Eleven-Year-Old Girl With Bilateral…

People living with hypoparathyroidism have blood levels of a key phosphate-regulating hormone more than four times higher than healthy individuals and show signs of stiffer arteries, a new study from Spain suggests. The findings highlight a potential link between the rare hormone disorder and an increased risk of cardiovascular…

After reviewing more than 12,000 cases of people who underwent surgery to remove all or part of the thyroid gland — a procedure called thyroidectomy, which is known to cause hypoparathyroidism, or low levels of a key hormone — a team of researchers in China has created a classification…

A new predictive model can now accurately identify which patients are at high risk of developing persistent hypoparathyroidism, a chronic complication of thyroid surgery, soon after the operation. Research from the Netherlands indicates that three simple clinical factors can be entered into…

The European Society of Endocrinology (ESE) has issued updated treatment guidelines for adults with chronic hypoparathyroidism, introducing changes such as the redefinition of when the disease becomes chronic after surgery and expanded guidance on when to use parathyroid hormone (PTH) replacement therapies. The recommendations were developed by a multidisciplinary team…

The approved therapy Yorvipath (palopegteriparatide) can improve kidney function in adults with hypoparathyroidism within months of initiating treatment, and these improvements are sustained for at least three years. That’s according to clinical trial data Yorvipath’s developer, Ascendis Pharma, shared this week at the annual meeting of…

People with chronic hypoparathyroidism who were prescribed the parathyroid hormone (PTH) replacement therapy Natpara had low health-related quality of life (HRQoL) and high symptom burden before starting treatment, according to a real-world study. The study compared patients who switched from conventional treatment to Natpara against those who stayed on…

A new study shows that Yorvipath (palopegteriparatide), a hormone replacement therapy, eliminates the need for conventional calcium and active vitamin D supplements in most adults with hypoparathyroidism. The therapy achieves this while keeping blood calcium levels stable and within the normal range. These findings come from a U.S.